Results 101 to 110 of about 6,511 (194)

Use of the dopamine agonist cabergoline in the treatment of movement disorders

, 2002
Cabergoline is an ergot-derived dopamine agonist used in the treatment of Parkinson's disease (PD). Both ergot and non-ergot-derived dopamine agonists directly stimulate dopamine receptors, unlike levodopa, which must undergo presynaptic breakdown to ...
Marco, Aimee Di, Chaudhuri, K Ray, Appiah-Kubi, Linda S   +2 more
core   +1 more source

Response to Treatment in a sample of Iraqi Patients with Prolactinoma

Medical Journal of Babylon
Background: Hyperprolactinemia is a common endocrine abnormality caused by physiological factors like pregnancy and lactation, drug-induced factors like antipsychotics, pituitary adenomas that secrete prolactin, or stalk compression or section that ...
Rana Kareem Mohammed, Abdullah Arnoos Abdulhasan, Shatha Mohammed Fezea   +2 more
doaj   +1 more source

Inhibiting prolactin by cabergoline accelerates mammary gland remodeling during the early dry period in dairy cows

, 2017
The inhibition of prolactin release using cabergoline, a dopamine agonist, is an effective strategy to accelerate the changes in mammary secretion composition after drying-off.
M. Boutinaud, N. Isaka, Gandemer, Eva, E. Gandemer, P. Lamberton, V. Lollivier, de Prado Taranilla, A.I., Lamberton, Philippe, Sordillo, L M, Wiart, Sandra, A. I. De Prado Taranilla, Isaka, N, Lollivier, Vanessa, Boutinaud, Marion, S. Wiart, L.M. Sordillo, De Prado Taranilla, A I   +16 more
core   +1 more source

A fatal overdose of the ergot derivative cabergoline

, 2004
Cabergoline,Whole blood,Poisoning ...
Johansen, Sys Stybe, Karkov, Jens Nissen Dyrlund   +1 more
core  

Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study

, 2007
The effectiveness of cabergoline in 50 men with psychogenic erectile dysfunction was investigated in a 4-month, randomized, placebo-controlled, double-blind study with validated psychological tests, and prolactin, follicle-stimulating hormone ...
Loew, T, Moleda, D, Rother, W, Nickel, M, Gil, F Pedrosa   +4 more
core   +1 more source

Comparison of the effects of cabergoline and bromocriptine in women with hyperprolactinemic amenorrhea

, 2008
Objective: There are relatively few reports in the world comparing the beneficial and adverse effects of bromocriptine and cabergoline in the treatment of hyperprolactinemic patients and there is also lack of such studies in Iraq.
Mahmood, Isam H., Al-Jubori, Zena S., Al-Husaynei, Ahmed J.   +2 more
core   +1 more source

Macroprolactinoma with progressive resistance to high-dose cabergoline

, 2006
Introduction True resistance to cabergoline in patients with hyperprolactinaemia has only rarely been reported. We describe a patient with macroprolactinoma who initially responded to cabergoline, but then developed a progressive increase in PRL levels ...
Ball SG, Lewis J, Arun CS, Quinton R, Hill J, Mitra D   +5 more
core  

Effect of cabergoline and metformin combination therapy in the treatment of infertile women with symptomatic endometrioma: comparison with cabergoline alone

Background: Endometrioma is a prevalent manifestation of endometriosis and a common cause of infertility in women of reproductive age. This study aimed to evaluate the effectiveness of cabergoline alone versus in combination with metformin in infertile ...
Islam, Jahirul, Banu, Jesmine, Ishrat, Shakeela, Lasker, Nastaran, Akter, Asma, Renu, Rafikunnahar, Laila, Rawnok, Islam, Tahmida, Chowdhury, Tanzina Iven   +8 more
core   +1 more source

Cabergoline for levodopa-induced complications in Parkinson\u27s disease

BACKGROUND: Long term levodopa therapy in Parkinson\u27s disease is associated with the development of motor complications including abnormal involuntary movements and a shortening response to each dose (wearing off phenomenon).
Deane KH; Clarke CE
core  

Impulse control disorders and their relationship with psychopathology in patients treated with cabergoline for hyperprolactinaemia. [PDF]

Pituitary
Zerbinati L, Cristilli G, Valier B, Braccia F, Okai D, Toffanin T, Verrienti M, Giampietro A, Grassi L, Zatelli MC, Ambrosio MR.   +10 more
europepmc   +1 more source